Get started
Author

Silvia Ríos‐Romenets

Observed names: Silvia Rios-Romenets, Silvia Rios‐Romenets, Silvia Ríos-Romenets
OpenAlex ID: A5042870626
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
2019 · Joseph F. Arboleda-Velasquez, Francisco Lopera, et al. · Nature Medicine · 597
Validation of the MDS clinical diagnostic criteria for Parkinson's disease
2018 · Ronald B. Postuma, Werner Poewe, et al. · Movement Disorders · 312
Movement disorder society criteria for clinically established early Parkinson's disease
2018 · Daniela Berg, Charles H. Adler, et al. · Movement Disorders · 168
PDF
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study
2020 · Yakeel T Quiroz, Henrik Zetterberg, et al. · The Lancet Neurology · 159
The Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal‐dominant Alzheimer's disease, including a placebo‐treated noncarrier cohort
2018 · Pierre N. Tariot, Francisco Lopera, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 128
PDF
Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease
2023 · Clara Vila‐Castelar, Yinghua Chen, et al. · Alzheimer s & Dementia · 33
PDF
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
2020 · Silvia Rios‐Romenets, Francisco Lopera, et al. · Alzheimer s & Dementia · 31
PDF
Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer’s disease
2023 · Stephanie Langella, N. Gil Barksdale, et al. · Nature Communications · 30
PDF
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
2021 · Valentina Ghisays, Francisco Lopera, et al. · NeuroImage Clinical · 28
Sex differences in cognitive resilience in preclinical autosomal‐dominant Alzheimer's disease carriers and non‐carriers: Baseline findings from the API ADAD Colombia Trial
2022 · Clara Vila‐Castelar, Pierre N. Tariot, et al. · Alzheimer s & Dementia · 27
Office-Based Screening for Dementia in Parkinson Disease
2018 · Benjamin K. Dawson, Seyed-Mohammad Fereshtehnejad, et al. · JAMA Neurology · 24
PDF
Examining Sex Differences in Markers of Cognition and Neurodegeneration in Autosomal Dominant Alzheimer’s Disease: Preliminary Findings from the Colombian Alzheimer’s Prevention Initiative Biomarker Study
2020 · Clara Vila-Castelar, Edmarie Guzmán-Vélez, et al. · Journal of Alzheimer s Disease · 20
The Colombian Alzheimer's Prevention Initiative (API) Registry
2016 · Silvia Rios‐Romenets, Hugo Lopez, et al. · Alzheimer s & Dementia · 19
A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal‐Dominant Alzheimer's Disease Trial
2022 · Eric M. Reiman, Jeremy J. Pruzin, et al. · Alzheimer s & Dementia · 13
PDF
Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease
2024 · Stephanie Langella, Kyra Bonta, et al. · Alzheimer s Research & Therapy · 9
PDF
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
2018 · Silvia Rios‐Romenets, Natalia Acosta‐Baena, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 9
PDF
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
2018 · Silvia Rios-Romenets, M. Giraldo-Chica, et al. · The Journal of Prevention of Alzheimer s Disease · 7
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
2026 · Pierre N Tariot, Francisco S Lopera, et al. · The Lancet Neurology · 4
Plasma p‐tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross‐sectional and longitudinal cohort study
2025 · Vincent Malotaux, Nicholas J. Ashton, et al. · Alzheimer s & Dementia · 2
API ADAD Colombia Trial initial findings: a randomized, double‐blind, placebo‐controlled, parallel‐ group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
2022 · Kaycee M. Sink, Rachelle S. Doody, et al. · Alzheimer s & Dementia · 2
Depression and anxiety disorder along life in familial Alzheimer’s disease in the API ADAD Colombia trial
2020 · Claudia Ramos, Silvia Rios‐Romenets, et al. · Alzheimer s & Dementia · 2
PDF
Strategies to promote contraception use by female volunteers in Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease (API ADAD) Colombia trial
2024 · Christian Bustamante, Juan F Martinez, et al. · Clinical Trials · 1
PDF
Longitudinal lumbar puncture adherence in the Alzheimer’s Prevention Initiative Autosomal‐Dominant Alzheimer’s Disease Colombia Trial
2023 · Natalia Acosta‐Baena, Silvia Ríos‐Romenets, et al. · Alzheimer s & Dementia · 1
PDF
Sex differences in neurodegeneration and memory performance in preclinical autosomal dominant Alzheimer’s disease: Baseline findings from the API ADAD trial
2020 · Clara Vila‐Castelar, Pierre N Tariot, et al. · Alzheimer s & Dementia · 1
PDF
Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia Trial
2026 · Tobias Bittner, Francisco Lopera, et al. · EBioMedicine
Works count: 46
Citation count: 1,627
H-index: 13
I10-index: 14
Year
Topic
Type